Recent Study: Qatar Pharmaceuticals & Healthcare Report Q3 2013
Despite its favourable risk profile in relation to most of its regional neighbours, we continue to see Qatar as a relatively modest longer-term commercial proposition for research-based pharmaceutical manufacturers, on account of its modest population size of less than two million. Nevertheless, a growing non-communicable disease burden should ensure consumption continues to rise in volume terms, especially as Qatar continues to invest in healthcare and research infrastructures.
View full press release